Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China

作者：Yunpeng Yang, Huaqiang Zhou, Lin‐Quan Tang, Sufang Qiu, Yaqian Han, Dongmei Ji, Xiaozhong Chen, Feng Lei, S Q Qu, Bin Deng, Lusi Chen, Jian-Li Huang, Ye Guo, Zhigang Liu, Dongping Chen, Jingao Li, Xiaolei Shu, Qin Yan, Zhichao Fu, Bihui Li, Peng Zhang, Shaoqing Chen, Jinsheng Hong, Wei Yan, Xintian Qin, Shenhong Qu, Kunyu Yang, Daren Lin, Junxian Wang, Lei Yang, Sa Xiao, Hai Zhu, Yi Zhu, Li Zhang · 发表于：The Lancet · 年份：2025 · DOI：10.1016/s0140-6736(25)01954-3 · 被引用次数：18 · 研究领域：Head and Neck Cancer Studies、HER2/EGFR in Cancer Research、Advanced Breast Cancer Therapies